Human Pharmaceutical Portfolio

Mabtas RA 500 mg Injection

Product information from the Times Medicament supplied portfolio. Contact our export team to confirm current sourcing options, market requirements and commercial availability.

Molecule / StrengthRituximab 500 mg
ManufacturerIntas Pharmaceuticals Ltd
CategoryAnti-Cancer
This product is listed in the supplied Times Medicament unregistered product portfolio. Listing does not by itself confirm registration, licensing or availability in any specific country. Market-specific confirmation is required.